Institutional investors purchased a net $957.4 thousand shares of PGNX during the quarter ended September 2013 and now own 85.05% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BLACKROCK FUND ADVISORS Bought 957.1 Thousand shares of Progenics Pharmaceuticals...